Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Monoclonal antibodies work differently from conventional drugs in that they can recognize unique antigens on the surface of leukemia cells. Alfa Cytology is a provider of antibody development services, supporting the development of therapeutic antibodies for leukemia. Using our state-of-the-art platform for advanced monoclonal antibody synthesis, as well as our team of experienced researchers, we provide comprehensive assistance for both research endeavors and the pursuit of potential therapeutic antibodies.
The approval of rituximab for the treatment of B-cell malignancies demonstrates the feasibility of using antibodies in leukemia therapy. Monoclonal antibodies, due to their precise specificity, demonstrate the exceptional capacity to selectively identify and attach to specific molecules found on the surface of leukemia cells. Through various mechanisms, such as direct cytotoxicity, induction of apoptosis, and inhibition of signal transduction, these antibodies effectively hinder the growth and viability of leukemia cells.
Fig. 1. Schema of different monoclonal antibodies. (Jabbour, E. et al., 2015)
Monoclonal antibodies are antibodies produced by cell lineages derived from the cloning of unique white blood cells. Monoclonal antibodies can act through various mechanisms, including direct cytotoxicity, immune-mediated cytotoxicity, vascular disruption, and modulation of the immune response. Alfa Cytology provides comprehensive monoclonal antibody development services, including but not limited to the following.
| Surface Antigen | Service Descriptions |
| CD20 CD22 CD19 |
Our extensive range of services encompasses the meticulous design of monoclonal antibodies that selectively target surface receptors unique to leukemia cells. We possess specialized expertise in formulating monoclonal antibodies that exhibit precise recognition of CD20, CD22, and CD19, thereby yielding invaluable insights into chronic lymphocytic leukemia (CLL) and B-cell acute lymphoblastic leukemia (B-ALL) treatment. |
| CD123 | Additionally, we offer tailored monoclonal antibody design services targeting refractory or relapsed leukemia by utilizing CD123 as a key target. By accelerating the development of new CD123-targeted therapies, we aim to provide innovative solutions to challenging cases. |
| CD33 CD3 |
Furthermore, our expertise extends to the design of antibodies against CD33, a marker associated with myeloid differentiation, and CD3, a hallmark of the T-cell lineage. These antibodies hold great potential for exploring the treatment of myeloid leukemia. |
| Others | As part of our expertise in leukemia immunotherapy, we offer a broad range of design options, including antibodies that target glycoproteins and oncogenic receptors, antibodies that target chemokine receptors, antibodies that target immune checkpoints, and antibodies that target the tumor niche. |
We can combine these leukemia cell-targeting monoclonal antibodies with cytotoxins or immunotoxins, further enhancing their therapeutic potential. The cytotoxins available for combination include but are not limited to, calicheamicin, Pseudomonas exotoxin A, PBD dimer, or any specific drug of your interest.
Our institute offers a comprehensive range of protocols for the development of leukemia-specific monoclonal antibodies in conjunction with methotrexate and cytarabine. Additionally, we offer method development services for the combined use of tyrosine kinase inhibitors like imatinib and monoclonal antibodies targeting leukemia. These services offer solutions for leukemia drug combination therapy and drug resistance, empowering you with effective strategies to combat the disease.
Customized
Solutions
Regulatory
Compliance
Timely
Delivery
Highly
Confidential
Alfa Cytology offers a wide range of integrated solutions for the development of leukemia-specific monoclonal antibodies. Through collaborative engagement with our institute, you can unlock the full potential of our extensive monoclonal antibody design services, enabling you to deepen your comprehension of leukemia biology and explore potential avenues for therapeutic interventions. Should you require further details about our comprehensive suite of services, please feel free to contact us.
Reference